Abstract
At JADPRO Live 2025, speakers discussed the latest safety and efficacy evidence behind recently approved therapies for myelodysplastic syndromes, implementing adverse event monitoring and management plans to support adherence and patient safety, and integrating current evidence into treatment decisions to reduce transfusion dependence and improve quality of life for patients with MDS.
